Plain-language summary

This Phase 2 trial is studying tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, and other medications for people with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone (DRUG): tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.

Drugs / treatments

tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details